Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability

Thrombosis and Haemostasis

Volumn 91, Issue 6, 2004, Pages 1115-1122

  Zarychanski, Ryan ^a   Houston, Donald S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

APC resistance; Homocysteine; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; CANADA; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HOMOCYSTINURIA; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATHOGENESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOSIS;

EID: 3042536588     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th04-01-0027     Document Type: Article

References (29)

1. Welch GN, Loscalzo J. Homocysteine and Atherothrombosis. N Engl J Med 1998; 338: 1042-50.
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischaemic heart disease and stroke. A meta-analysis. JAMA 2002; 288: 2015-22.
3. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
4. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis; a meta-analysis. Thromb Haemost 1998; 80: 874-7.
5. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from meta-analysis. BMJ 2002; 325: 1202-8.
6. Khajuria A, Houston DS. Pathogenesis of hyperhomocysteinemia - new insights. Hematology 2001; 6: 217-30.
7. Svensson P, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
8. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of Hyperhomocysteinemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-82
9. Bernardi F, Faioni EM., Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-57.
10. de Visser MC, Rosendaal ER, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-76.
11. Tirado I, Mateo J, Oliver A, et al. Patients with venous thromboembolism have a lower APC response than controls. Should this be regarded as a continuous risk factor for venous thrombosis? Haematologica 1999; 84: 470-2.
12. Graf LL, Welsh CH, Qamar Z, et al. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden. Am J Clin Pathol 2003; 119: 52-60.
13. Clark P, Walker I. The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001; 115: 767-73.
14. Undas A, Williams EB, Butenas S, et al. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem 2001; 276: 4389-97.
15. Lentz SR, Piegors DJ, Fernandez JA, et al. Effect of hyperhomocysteinaemia on protein C activation and activity. Blood 2002; 100: 2108-12.
16. Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: Sex differences and correlation with cobalamine and folate concentrations in healthy subjects. Clin Chem 1994; 40: 873-81.
17. Fiskerstrand T, Refsum H, Kvalheim G, et al. Homocysteine and other thiols in plsma and urine: automated determination and sample stability. Clin Chem 1993; 39: 263-71.
18. Kirschbaum NE, Foster PA. The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance. Thomb Haemost 1995; 74: 874-8.
19. Clarke R, Woodhouse P, Ulvik A, et al. Variability and determinants of total homocysteine concentrations in plasma in an elderly population. Clin Chem 1998: 44; 102-7.
20. Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996: 7; 761-5.
21. Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995: 74; 1198-9.
22. Viganò S, Mannucci PM, D'Angelo A, et al. Protein C antigen is not an acute phase reactant and is often high is ischemic heart disease and diabetes. Thromb Haemost 1984: 52; 263-6.
23. Aboud MR, Ma DD. Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance. Clin Lab Haematol 2001: 23; 411-6.
24. Clark P, Walker I. The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001: 115; 767-73.
25. Høibraaten E, Mowinckel MC, de Ronde H, et al. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double blind, placebo controlled trial. Br J Haematol 2001: 115; 415-20.
26. Soria JM, Almasy L, Souto JC, et al. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 2003; 101: 163-7.
27. ras methylation in vascular endothelial cells by homocysteine but not by cysteine. J Biol Chem 1997; 272: 25380-83.
28. Brown JC, Rosenquist TH, Monaghan DT. ERK2 activation by homocysteine in vascular smooth muscle cells. Biochem Biophys Res Commun 1998; 251: 669-76.
29. Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood 2000; 96: 966-72.